A simple scoring model for advanced colorectal neoplasm in asymptomatic subjects aged 40–49 years

Yoo Mi Park1,2†, Hee Sun Kim2†, Jae Jun Park1*, Su Jung Baik2, Young Hoon Youn1, Jie-Hyun Kim1 and Hyojin Park1

Abstract

Background: Limited data are available for advanced colorectal neoplasm in asymptomatic individuals aged 40–49 years. We aimed to identify risk factors and develop a simple prediction model for advanced colorectal neoplasm in these persons.

Methods: Clinical data were collected on 2781 asymptomatic subjects aged 40–49 years who underwent colonoscopy for routine health examination. Subjects were randomly allocated to a development or validation set. Logistic regression analysis was used to determine predictors of advanced colorectal neoplasm.

Results: The prevalence of overall and advanced colorectal neoplasm was 20.2 and 2.5% respectively. Older age (45–49 years), male sex, positive serology of Helicobacter pylori, and high triglyceride and low high-density lipoprotein (HDL) levels were independently associated with an increased risk of advanced colorectal neoplasm. BMI (body mass index) was not significant in multivariable analysis. We developed a simple scoring model for advanced colorectal neoplasm (range 0–9). A cutoff of ≥4 defined 43% of subjects as high risk for advanced colorectal neoplasm (sensitivity, 79%; specificity, 58%; area under the receiver operating curve = 0.72) in the validation datasets.

Conclusion: Older age (45–49 years), male sex, positive serology of H. pylori, high triglyceride level, and low HDL level were identified as independent risk factors for advanced colorectal neoplasm.

Keywords: Adenoma, Colonoscopy, Colorectal neoplasm, Risk assessment, Screening

Background

Colorectal cancer (CRC) is one of the most prevalent cancers with a high incidence in Western countries [1]. The incidence of CRC has increased approximately 2–4 times in the past decades in many Asian countries [2, 3]. Because most CRC develops through the adenoma–carcinoma sequence [4], CRC can be prevented by colonoscopy with polypectomy of premalignant lesions. With respect to the screening age of CRC, since there is a significant increase in the incidence of CRC during the sixth decade of life, most CRC guidelines recommend that screening colonoscopy begin at age 50 for asymptomatic, average-risk individuals [5–7].

Although the frequency of colon cancer over 50 years has decreased in Western countries, the incidence of CRC has increased in 12 per 100,000 in 1987 to 18 per 100,000 in 2006, which is a 50% increase over 20 years among persons aged 40–44 years [8]. Persons younger than 50 years of age account for 7–9% of those diagnosed with CRC, and they tend to present with more advanced disease and have a less favorable prognosis than those older than 50 [9]. These clinical characteristics of younger persons with CRC may be associated with a time delay in diagnosis; hence, current CRC screening guidelines exclude the younger population. To minimize the amount of younger CRC patients who are not captured by the screening program, a tailored approach based on the risk of advanced adenoma that considers cost-effectiveness may be needed because the prevalence of colonic neoplasm in this age group is significantly lower than that in those aged ≥50 years [10, 11].
Regarding advanced adenoma, which is the most reliable target lesion for CRC screening, several markers, including the westernization of lifestyles, obesity, and metabolic syndrome, have been reported as risk factors for this neoplasm in the younger population, especially in those aged 40–49 years. Although these risk factors can be tailored in CRC screening for the younger age group, the systematic application of scattered risk factors may be limited in daily clinical practice. Therefore, the aim of this study was to identify risk factors and develop a simple prediction model for advanced colorectal neoplasm in asymptomatic individuals aged 40–49 years.

Methods
This study was conducted in two steps. First, we identified risk factors associated with the occurrence of advanced colorectal neoplasm in the development set, and developed a simple scoring model for the prediction of advanced colorectal neoplasm based on independent risk factors. Subsequently, we evaluated the clinical effectiveness of a prediction model for advanced neoplasm in the validation set. This study was approved by the institutional review board of Gangnam Severance Hospital.

Study population
A cross-sectional study was conducted with 2781 asymptomatic adults aged 40–49 years who underwent screening colonoscopy for the first time from January 2008 to January 2012 at the Health Promotion Center of the Gangnam Severance Hospital in Seoul, South Korea. We excluded the following criteria: 1) previous colorectal examinations, including colonoscopy, sigmoidoscopy, or barium enema; 2) colonoscopies that had inadequate bowel preparation and did not reach the cecum; 3) individuals who had a personal history of colorectal neoplasm and inflammatory bowel disease; 4) a history of colorectal surgery, and 5) any symptoms, weight loss, anemia, or bleeding. Subjects were randomly allocated to a development or validation set in a 2:1 ratio.

Colonoscopy
Bowel preparation was performed using 4 L of polyethylene glycol solution, and subjects underwent a 3-day dietary restriction. The quality of bowel preparation was determined by the physician who used the following descriptors: excellent, good, fair/adequate, inadequate, and poor. Those that were inadequate and poor were labeled as poor preparation and were not included in the final analysis. Colonoscopies were performed by four endoscopists who had performed a minimum of 1000 colonoscopies, and all endoscopists were gastroenterology fellowship-trained and board-certified in their respective field. All examinations were performed using a standard video colonoscope (CF-H260AI; Olympus, Tokyo, Japan). All detected polyps were biopsied or removed. All polyp characteristics such as the size, number, shape, and location were documented. Polyp size was grossly estimated using open-biopsy forceps (Olympus FB-28U-1; Aomori Olympus Co., Ltd., Aomori, Japan). The polyp shape was classified as sessile (Is), semipedunculated (Isp), or pedunculated (Ip) type [12].

Data collection
Subjects’ information, including demographics, laboratory tests, colonoscopic findings, and pathology reports, by review of electronic medical records was collected. Age was categorized into two groups: 40–44 years and 45–49 years. Body mass index (BMI) was categorized by the Western Pacific Regional Office of the World Health Organization criteria: normal (≤23 kg/m^2), overweight (23–24.9 kg/m^2), or obese (≥25 kg/m^2) [13]. According to the American Joint Committee’s (Joint National Committee) seventh report, blood pressure was classified as normal (<120/80 mmHg), prehypertension (120–139/80–89 mmHg), or hypertension (≥140–90 mmHg or taking antihypertensive drugs). Laboratory tests included immunoglobulin G specific for Helicobacter pylori, which was screened by an enzyme-linked fluorecence assay in each serum (ELFA, enzyme-linked via Vidas; bioMerieux Vitek, Inc., USA); elevated total cholesterol (≥240 mg/dL); elevated triglycerides (≥200 mg/dL); elevated low-density cholesterol (≥100 mg/dL); and low high-density lipoprotein cholesterol (HDL-c, <40 mg/dL). All lipid and lipoprotein levels were measured using a Hitachi 7600 Modular Dp-110 auto-analyzer, which included enzymatic colorimetric tests. Based on the normal reference range, serum lipid profiles were classified as normal or abnormal results.

We collected polyp data from colonoscopy reports. Advanced colorectal neoplasms were defined as follows: 1) CRC; 2) adenoma with a diameter of ≥10 mm; 3) tubular adenoma with high-grade dysplasia; and 4) tubulovillous or villous adenoma. When two or more adenoma were detected, the most advanced lesion was analyzed based on the largest diameter or advanced histology. All polyps were evaluated histologically by gastroenterology pathologists.

Statistical analysis
Continuous variables were presented as mean ± standard deviation, and categorical variables were expressed as percentages. Continuous variables were compared using Student t-test, whereas categorical variables were compared using chi-square or Fisher exact tests. For prediction model development, differences between variables were compared in the training set. Before univariate analysis, continuous variables were converted to categorical
Variables with a P-value <0.1 in univariate analysis were included in subsequent multivariate regression analysis in order to select variables to be implemented in the final model. Backward elimination (i.e., removing the covariate with the largest P value, one at a time) was performed until we developed a final model with statistically significant covariates. We established a risk score model by excluding less significant variables in a risk assessment. We intentionally only used categorized variables that captured easy but relevant and validated information in the prediction model to develop an easy to use screening score. We used a weighted scoring system by rounding down odds ratios (ORs) to the nearest integer in the final model. For example, an OR of 1.96 was rounded to 1 and an OR of 2.26 was rounded to 2. Based on this statistical analysis, we developed a formula for predicting asymptomatic subjects aged 40–49 years with advanced neoplasm, and these subjects may be primary candidates for screening colonoscopy. To validate the model, we assessed the diagnostic accuracy of the model in the validation set. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated using the computed area under receiver operating characteristic curve (AUROC). Thereafter, we validated the diagnostic value of the scoring model.

All analyses were performed using SPSS software (version 20.0; SPSS Inc.) and MedCalc software (version 11.1; Mariakerke) for the receiver operating characteristic analysis.

Results
Baseline characteristics of the total subjects
Among 2781 subjects, mean age was 44.8 ± 2.8 years, and 58.7% (1633/2781) were men. Helicobacter serology positivity was observed in 1623 (58.4%) patients. Regarding the prevalence of colorectal neoplasm, advanced neoplasm was detected in 70 (2.5%) of patients, whereas any type of colorectal neoplasm was found in 561 (20.2%) of patients. Baseline characteristics of 2781 patients in the training and validation sets are summarized in Table 1. There was no statistically significant difference in patient characteristics between the training and validation sets.

Clinicopathological characteristic of the colorectal neoplasm
Details of the clinicopathological findings of neoplasm are summarized in Table 2. Among 561 neoplasms, 64 (11.4%) were larger than 10 mm, 537 (95.7%) had a low-grade tubular adenoma, and 24 (4.3%) had advanced neoplasm, including 2 patients (0.4%) with cancer.

Factors associated with advanced colorectal neoplasm in the development dataset
Univariate analysis showed that male sex (P ≤ 0.001), the obese group (P = 0.016), positive serology of H. pylori (P = 0.009), low HDL level (P ≤ 0.001), and high triglyceride level (P ≤ 0.001) were significantly associated with the presence of advanced neoplasm. Moreover, the older age group (45–49 years) was marginally associated with the presence of advanced neoplasm (P = 0.053). Details of the statistical analysis are summarized in Table 3. In subsequent multivariate analysis, the older age group (OR 1.967, 95% CI 1.191–3.749, P = 0.040), male sex (OR 2.763, 95% CI 1.032–6.409, P = 0.018), positive serology of H. pylori (OR 2.262, 95% CI 1.108–4.621, P = 0.025), low HDL level (OR 2.219, 95% CI 1.073–4.308, P = 0.031), and high triglyceride level (OR 1.967, 95% CI 1.143–4.252, P = 0.018) were identified as independent factors for advanced neoplasm. BMI (body mass index) was not significant in multivariable analysis. Details of these values are depicted in Table 4.
A simple scoring model was constructed based on five independently significant variables in multivariate analysis by using rounded down ORs of each variable (Table 4). The final model is as follows:

\[
\text{A simple scoring model for advanced colorectal neoplasm} = \text{Age} [0: \geq 45 \text{ years}] \times 1 + \text{Sex} [0: \text{female}, 1: \text{male}] \times 2 + \text{Serology of } H. \text{pylori} [0: \text{negative}, 1: \text{positive}] \times 2 + \text{High triglyceride level} [0: \text{normal range}, 1: \text{high}] \times 2 + \text{Low HDL level} [0: \text{normal range}, 1: \text{low}] \times 2
\]

The range of the total score for this risk model was 0–9. This model yielded an AUROC of 0.74 for predicting advanced neoplasm in the development set (Fig. 1a).

### Development of a simple scoring model for predicting advanced neoplasm

A simple scoring model was constructed based on five independently significant variables in multivariate analysis by using rounded down ORs of each variable (Table 4). The final model is as follows:

\[
\text{A simple scoring model for advanced colorectal neoplasm} = \text{Age} [0: \geq 45 \text{ years}] \times 1 + \text{Sex} [0: \text{female}, 1: \text{male}] \times 2 + \text{Serology of } H. \text{pylori} [0: \text{negative}, 1: \text{positive}] \times 2 + \text{High triglyceride level} [0: \text{normal range}, 1: \text{high}] \times 2 + \text{Low HDL level} [0: \text{normal range}, 1: \text{low}] \times 2
\]

The range of the total score for this risk model was 0–9. This model yielded an AUROC of 0.74 for predicting advanced neoplasm in the development set (Fig. 1a).

### Validation of the scoring model in the validation set

We investigated the predicted value of different total score cut points in the validation sets (Table 5). A cutoff point of 4 was selected because it results in the highest value for the AUROC to indicate an individual at high risk for advanced neoplasm. In the validation set, this cutoff point designated 43.1% of subjects at high risk for advanced colorectal neoplasm, and yielded a sensitivity of 79.2%, specificity of 57.8%, PPV of 4.7%, and NPV of 99.1% with an AUROC of 0.72 (Fig. 1b). The prevalence of advanced neoplasm gradually increased as the total risk score increased, and these findings are depicted in Fig. 2.

### Discussion

To the best of our knowledge, our study is the first study to propose a prediction model for advanced neoplasm in the 40–49-year-old population. In the 40–49-year-old group, an increased risk of advanced neoplasm was associated with those aged \( \geq 45 \) years, male sex, positive serology of \( H. \text{pylori} \), and high triglyceride and low HDL levels. We developed a simple scoring model for...
predicting advanced colorectal neoplasm (range 0–9), and a cutoff point of \( \geq 4 \) in this model yielded a sensitivity of 78% and specificity of 56% (AUROC = 0.74) (data not shown). Comparable results were obtained in the validation datasets (sensitivity 79%, specificity 58%, and AUROC = 0.72).

It has been reported that the prevalence of advanced colorectal neoplasm in individuals aged 40–49 years is 1.3–3.5% [10, 14–17]. Similar to these results, our study showed a 2.5% prevalence for advanced neoplasm in an asymptomatic population. Currently, advanced adenoma is regarded as the most feasible target for CRC screening [2, 6, 7]. Based on our prediction model, the prevalence of advanced neoplasm gradually increased as the risk score increased. This finding suggests that our prediction model can be a reliable tool for identifying target subjects for CRC screening among persons aged 40–49 years. Our prediction model produced moderate accuracy for predicting advanced neoplasm, producing an AUROC value of 0.72 in the validation cohort.

Regarding age-related risk stratification, our study showed that the risk for advanced neoplasm was approximately two times higher in the 45–49 age group than in the 40–44 age group. This finding suggests that further subgroup classification can be helpful in identifying the population at risk within the 40–49 age group, and it was eventually incorporated into our prediction model. Similar to our results, Hong et al. [10] also reported that the 45–49 age group had a high adjusted OR of 1.68 compared to the 40–44 age group for detecting advanced neoplasm.

Among lipid profile indices, we found that hypertriglyceridemia and low HDL-c were independently associated with advanced neoplasm. In accordance with our findings, a previous study showed that higher levels of serum triglyceride were significantly associated with an increasing prevalence of both non-advanced and advanced colorectal adenoma in a population aged 40–79 years [18]. Concerning the association between hypertriglyceridemia and advanced neoplasm, although the exact mechanism is currently unclear, several mechanisms have been suggested. First, hyperinsulinemia and insulin resistance is affected by apoptosis, thereby a lower rate of apoptosis in normal colonic mucosa is associated with the carcinogenesis process, and they may develop into colorectal adenoma, or even cancer [19–21]. Second, hypertriglyceridemia can also increase proinflammatory cytokine levels, and damage deoxyribonucleic acid. These also affect carcinogenesis through abnormal growth, apoptosis, and the proliferation of colorectal cells [22–24].

Meanwhile, similar to our results of association between a low HDL-c level and the risk of advanced neoplasm, trends for an increased prevalence of advanced adenoma with decreasing levels of HDL cholesterol was also found in previously reported data [18]. Other studies have also shown that a reduction in HDL cholesterol levels slightly increases the risk of adenomatous colon polyps, and consequently colon cancer [25, 26]. Although the underlying mechanism for the relationship

| Table 4 Multivariate regression analysis in the development set |
|-----------------|-----------------|-----------------|-----------------|
| Odds ratio      | P-value         | Score assigned  |
| (95% CI)        |                 |                 |
| Older age (45–49 years) | 1.967 (1.191–0.040) | 0.040 | 1 |
| Male sex        | 2.763 (1.032–0.018) | 0.018 | 2 |
| Positive serology of H. pylori | 2.262 (1.108–0.025) | 0.025 | 2 |
| High triglyceride level | 2.219 (1.073–0.031) | 0.031 | 2 |
| Low HDL-c       | 2.136 (1.143–4.252) | 0.018 | 2 |

CI confidence interval, H. pylori, Helicobacter pylori, HDL-c high-density lipoprotein cholesterol

A simple scoring model for advanced colorectal neoplasm = Age [0: 40–44, 1: 45–49 years] \times 1 + Sex [0: female, 1: male] \times 2 + Serology of H. pylori [0: negative, 1: positive] \times 2 + Triglyceride level [0: normal range, 1: high] \times 2 + High-density lipoprotein level [0: normal range, 1: low] \times 2

Fig. 1 Area under the receiver operating characteristic (AUROC) curve of the simple scoring model for advanced neoplasm in subjects aged 40–49 years. An AUROC of 0.74 (95% confidence interval [CI] 0.717–0.757) in development set (a) and an AUROC of 0.72 (95% CI 0.695–0.753) in the validation set (b).
between a low HLD level and the risk of advanced neoplasm is still elusive, a low HDL level may result from interactions with triglyceride and HDL cholesterol, and the aforementioned possible molecular mechanism associated with hypertriglyceridemia and colonic adenoma may also be involved in these processes. Further extensive molecular biological studies are needed to clarify the association between dyslipidemia and the risk of colonic neoplasm.

An association between colorectal neoplasm and H. pylori infection has been steadily suggested, and meta-analysis data also demonstrated that H. pylori infection increase the risk of colorectal neoplasm by 1.4–1.6 times [27]. In addition, a recent large cross-sectional study showed that the OR of the group with H. pylori gastritis is about 1.24–2.35 [28]. In accordance with these observations, our study also showed that patients with H. pylori infection are 2.26 times more likely to have advanced neoplasm compared to patients without H. pylori infection in subjects aged 40–49 years. Although the relationship between H. pylori infection and increased risk of colorectal adenoma is unclear, several pathogenic mechanisms have been suggested. Increased gastrin induced by H. pylori infection may contribute to carcinogenesis by cell proliferation in the colon mucosa, and H. pylori itself can act on the colorectal epithelium through inflammatory responses and affect polyp growth or promote mucosal dysplasia [29–31].

There are several advantages to our study. First, our prediction model was developed based on a large study population that included 1844 and 937 asymptomatic subjects in the training and validation cohort, respectively. Second, our model consisted of basic demographic factors and readily available serologic indices. Moreover, the final score of our model can be calculated in daily practice; thus, it has potential for high clinical utility in selective screening colonoscopy among the 40–49-year-old population. Lastly, our model allows for the adjustment of a cutoff value for subgroup targeting based on population characteristics and endoscopic resources. Several limitations of our study should be mentioned. First, this study was performed in a health promotion center of a single university hospital in Korea. Therefore, generalizability of our results to the general population and other ethnicities is uncertain. Second, our study did not include lifestyle factors such as drinking, smoking, physical activity, and medication history. It has been reported that these lifestyle factors and some drugs are associated with the development of colorectal neoplasm [32–34]. Nevertheless, previous data have shown that some lifestyle factors, including smoking, alcohol, and medication, use were not significant predictors of advanced neoplasm in average risk screenees aged 40–49 years [10]. Hypertriglyceridemia is associated with alcohol consumption and a degree of smoking. Moreover, low HDL levels are related with a smoking habit, and its value in serum can be increased by regular exercise [35–38]. These observations imply that lipid indices can partly reflect lifestyle characteristics of each single person, and these lipid indices are incorporated in our prediction model. Finally, the retrospective nature of this study poses some limitations. However, our data were gathered prospectively, and our model largely consisted of objective results of serology, which were measured on the same day of colonoscopy. Thus, the influence of this limitation seems to be minimal. Further prospective studies incorporating diverse demographic, clinical, and serological parameters should be conducted.

Conclusions
In conclusion, older age (45–49 years), male sex, positive serology of H. pylori, and high triglyceride and low HDL

---

**Table 5** Performance of the simple scoring model in the validation datasets (n = 937)

| Score | High risk (%) | Sensitivity | Specificity | PPV | NPV | AUROC |
|-------|---------------|-------------|-------------|-----|-----|--------|
| ≥0    | 100           | 100         | 0           | 2.8 | 0   | 0.50   |
| ≥1    | 90.2          | 100         | 10.1        | 2.8 | 100 | 0.55   |
| ≥2    | 81.1          | 95.8        | 19.3        | 3.0 | 99.4| 0.58   |
| ≥3    | 64.2          | 87.5        | 36.4        | 3.5 | 99.1| 0.62   |
| ≥4    | 43.1          | 79.2        | 57.8        | 4.7 | 99.1| 0.72   |
| ≥5    | 30.3          | 62.5        | 70.5        | 5.3 | 98.6| 0.68   |
| ≥6    | 13.6          | 37.5        | 87.1        | 7.1 | 98.1| 0.62   |
| ≥7    | 8.0           | 25.0        | 92.4        | 8.0 | 97.9| 0.59   |
| ≥8    | 3.4           | 8.3         | 96.7        | 6.2 | 97.6| 0.53   |
| ≥9    | 1.5           | 4.2         | 98.6        | 7.1 | 97.5| 0.51   |

**PPV** positive predictive value, **NPV** negative predictive value, **AUROC** area under the receiver operating characteristic curve

---

**Fig. 2** Estimated prevalence of advanced neoplasm according to the risk score in the validation set. The proportion of subjects with scores of 0–1, 2–3, 4–5, 6–7, and 8–9 correspond to 0.6%, 1.5%, 3.0%, 6.0%, and 13.0%, respectively. A cutoff point of ≥4 (sensitivity 79%, specificity 58%) indicates that 43% of subjects are at high risk for advanced colorectal neoplasm
levels were identified as independent risk factors for advanced colorectal neoplasm. A simple scoring model that consists of five parameters may be useful for selecting patients who benefit from screening colonoscopy in asymptomatic persons aged 40–49 year. We hope that researchers will evaluate the performance of our prediction model in an independent population to confirm and validate our results.

Acknowledgements
Not applicable.

Funding
This research received no specific grant.

Availability of data and materials
All data analyzed during this study are included in this published article.

Authors' contributions
Study concept and design, analysis and interpretation of data, statistical analysis, and drafting of manuscript: JMP, MD, PhD. Acquisition of data: JMP, MD and HSK, MD, PhD. Study supervision for important intellectual content: SJB, JHK YHY, and HJP, MD, PhD. Study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content: JIP, MD, PhD. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study protocol and amendment were approved by the Institutional Review Board of Yonsei university hospital (IRB-3-2015-0030). All enrolled patients provided written informed consent.

Author details
1Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonjuro, Gangnam-gu, Seoul 135-720, South Korea.
2Health Promotion Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Received: 4 July 2016 Accepted: 16 December 2016
Published online: 09 January 2017

References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
2. Sung JJ, Lau JY, Goh KL, Leung WK, Asia Pacific Working Group on colorectal C. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6(11):871–6.
3. Toyoda Y, Nakayama T, Ito Y, Ioka A, Tsukuma H. Trends in colorectal cancer incidence by subsite in Osaka, Japan. Jpn J Clin Oncol. 2009;39(3):189–91.
4. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma–carcinoma sequence in large bowel. Lancet. 1978;1(8058):245–7.
5. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woof S, Johnson D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—Update based on new evidence. Gastroenterology. 2003;124(2):544–60.
6. Davila RE, Rajan E, Baror TH, Adler DG, Egan JV, Faigel DO, Gan SI, Hirota WK, Leighton JA, Lichtenstein D, et al. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc. 2006;63(4):546–57.
7. Lee BJ, Hong SP, Kim SE, Kim SH, Kim HS, Hong SN, Yang DH, Shin SJ, Lee SH, Park OI, et al. Korean guidelines for colorectal cancer screening and polyp detection. Clin Endosc. 2012;45(1):25–43.
8. Wachter K. Colorectal cancer rates up in people aged 40 to 44. GI & Hepatology News. AGA Institute. 2010;K1–4.
9. Fairley TL, Cardinale CJ, Martin J, Alley L, Friedman C, Edwards B, Jamison P. Colorectal cancer in US adults younger than 50 years of age. 1998–2001. Cancer. 2006;107(5):1153–61.
10. Hong SN, Kim JH, Cho WJ, Han HS, Sung IK, Park HS, Shin CS. Prevalence and risk of colorectal neoplasms in asymptomatic, average-risk screening 40 to 49 years of age. Gastrointest Endosc. 2010;72(3):480–9.
11. Thoma MN, Castro F, Golwala M, Chen R. Detection of colorectal neoplasia by colonoscopy in average-risk patients age 40–49 versus 50–59 years. Dig Dis Sci. 2011;56(5):1503–8.
12. The Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58(6 Suppl):S43-53.
13. Anuarad E, Shiwaku K, Nogi A, Kitajima K, Enkhmaa B, Shimo no K, Yamane Y. The new BMI criteria for亚洲 by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elderly Japanese workers. J Occup Health. 2003; 45(6):335–43.
14. Imperiale TF, Wagner DR, Lin CI, Larkin GN, Rogoff JD, Ransohoff DF. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med. 2002;346(23):1781–5.
15. Rundle AG, Lebowitz B, Vogel R, Levine S, Neugut AI. Colorectal screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology. 2008;134(5):1311–5.
16. Chung SJ, Kim YS, Yang SY, Song JH, Park MJ, Kim JS, Jung HC, Song IS. Prevalence and risk of colorectal adenoma in asymptomatic Koreans age 40–49 years undergoing screening colonoscopy. J Gastroenterol Hepatol. 2010;25(3):519–25.
17. Liu HH, Wu MC, Peng Y, Wu MS. Prevalence of advanced colonic polyps in asymptomatic Chinese. World J Gastroenterol. 2005;11(30):7471–4.
18. Yang MH, Rampal S, Sung J, Choi YH, Son HJ, Lee JH, Kim YH, Chang DK, Rhee PL, Kim JI, et al. The association of serum lipids with colorectal adenomas. Am J Gastroenterol. 2013;108(5):833–41.
19. Buchefield CM, Abbott RD, Curb JD, Sharp DS, Rodriguez Bl, Arakaki Y, Kano K. Association of insulin levels with lipids and lipoproteins in elderly Japanese-American men. Ann Epidemiol. 1998;8(2):92–8.
20. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131(11 Suppl):3105–20.
21. Martin C, Connelly A, Keku TO, Mountridge SB, Galanko J, Wooley JT, Schieber B, Lund PK, Sandler RS. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology. 2002;123(6):1770–7.
22. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–32.
23. Tabuchi M, Kitayama J, Nagawa H. Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men. World J Gastroenterol. 2006;12(8):1261–4.
24. Lee HL, Son BK, Lee OY, Jeon YC, Lee DS, Sohn JH, Yoon BC, Choi HS, Hams J, Lee MH, et al. Abdominal obesity, insulin resistance, and the risk of colon adenoma. Korean J Gastroenterol = Taehan Sohwagi Hakhoe chi. 2007;49(3):147–51.
25. Baverstocker E, Mannes GA, Ricter OW, Ochsenkuhn T, Seelhorster G, Kopcke W, Wiebecke B, Paumgartner G. Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann Intern Med. 1993;118(7):481–7.
26. Kono S, Honjo S, Todoroki I, Nishiwaki M, Hamada H, Nishikawa H, Koga H, Ogawa S, Nakagawa K. Glucose intolerance and adenomas of the sigmoid colon in Japanese men (Japan). World J Gastroenterol. 2006;12(5):1261–4.
27. Zhao YS, Wang F, Chang D, Han B, You DY. Meta-analysis of different test indicators: Helicobacter pylori infection and the risk of colorectal cancer. Int J Colorectal Dis. 2011;26(5):497–504.
28. Sonnenberg A, Gorbach RL. Helicobacter pylori is a risk factor for colorectal neoplasms: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58(6 Suppl):S43-53.
29. Nozawa T, Koyama K, Nishi Y, Tsuruta T, Ohgi R, Aso T, et al. Prevalence and risk of colorectal neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58(6 Suppl):S43-53.
30. Georgopoulos SD, Polymeros D, Triantafyllou K, Spiliadi C, Mentis A, Hahm JS, Lee MH, et al. Abdominal obesity, insulin resistance, and the risk of distal colon adenomas. Digestion. 2006;74(1):42–8.
31. Jones M, Helliwell P, Pritchard C, Tharakan J, Mathew J. Helicobacter pylori in colorectal neoplasms: is there an aetiological relationship? World J Surg Oncol. 2007;5:51.
32. Giovannucci E, Colditz GA, Stampfer MJ, Hunter D, Rosner BA, Willett WC, Speizer FE. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst. 1994;86(3):192–9.

33. Cho E, Smith-Warner SA, Ritz J, van den Brandt PA, Colditz GA, Folsom AR, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med. 2004;140(8):603–13.

34. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914–23.

35. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ. 1989;298(6676):784–8.

36. Celada MM, Reguero JR, Cubero GI. The interrelationship among tobacco consumption, high-density lipoprotein cholesterol and leukocyte counts. J Cardiovasc Risk. 1997;4(4):279–81.

37. Connelly PW, Petrasovits A, Stachenko S, MacLean DR, Little JA, Chockalingam A. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentaryness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group. Can J Cardiol. 1999;15(4):428–33.

38. Hata Y, Nakajima K. Life-style and serum lipids and lipoproteins. J Atheroscler Thromb. 2000;7(4):177–97.

---

Submit your next manuscript to BioMed Central and we will help you at every step:
- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit